Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension

NCT07577973 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06
Last updated
2026-05-14

Condition(s) studied

PRIMARY HYPERTENSION

Investigational drug(s) / intervention(s)

Real Acupressuresham acupressureUsual Care

Real Acupressure: Acupressure applied to HT7 (Shenmen), LI4 (Hegu), PC6 (Neiguan) bilaterally, and EX3 (Yintang). Pressure applied for 15 seconds per point, 3 days per week for 2 weeks by trained researcher. Total session duration approximately 1 minute.

sham acupressure: light pressure applied to non-acupoint sites 1-1.5 cm from HT7İLI4,PC6 and EX3 points for 15 seconds per site,3 days per week for 2 weeks

Usual Care: Standard hypertension management including prescribed antihypertensive medication and routine clinical nursing follow-up for 2 weeks. No acupressure applied.

Study summary

This randomized controlled trial examines the effects of nurse-led self-acupressure at HT7, LI4, PC6, and EX3 points on blood pressure, stress, and well-being in adults with primary hypertension. Participants are randomized to real acupressure, sham acupressure, or usual care groups for 2 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 18-65 years 2. Diagnosed with primary hypertension (Stage 1 or 2) 3. Systolic blood pressure 130-179 mmHg or diastolic 80-109 mmHg 4. Taking antihypertensive medication 5. Able to understand and communicate in Turkish 6. Willing to provide written informed consent Exclusion Criteria: 1. Secondary hypertension 2. Pregnancy or lactation 3. Severe cardiovascular disease (heart failure, myocardial infarction within 6 months) 4. Stroke history within 6 months 5. Skin lesions or infection at acupressure sites (HT7, LI4, PC6, EX3) 6. Peripheral neuropathy affecting sensation 7. Current use of anticoagulant therapy 8. Participation in another clinical trial within 30 days

Primary outcome measure(s)

  • change in blood pressure — baseline and week 2
    change from baseline in systolic and diastolic blood pressure measured using an automated office blood pressure monitor at 2 weeks

Trial sites (1)

FacilityCityRegionStatus
A Family Health Center in Duzce Düzce Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07577973 on ClinicalTrials.gov ↗ ← All trials in Turkey